Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow mesenchymal stem cells + pioglitazone
- Development stage
- Unknown
- Lead developer
- Royan Institute
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies
- Administration
- Intraportal, Oral
01
Overview
This investigational combination therapy, developed by the Royan Institute, consists of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) and the small molecule pioglitazone for the treatment of compensated liver cirrhosis. The BM-MSCs are harvested from the patient's own bone marrow and administered via intraportal injection to utilize their immunomodulatory, anti-fibrotic, and regenerative properties. Pioglitazone, a PPAR-gamma agonist, is administered concurrently to potentially enhance the anti-fibrotic effects and improve liver function. This dual approach aims to reduce liver fibrosis and promote tissue repair in patients for whom liver transplantation is the only current definitive treatment.
- Other names
- Combined Pioglitazone Plus Autologous Bone Marrow Mesenchymal Stem Cell TransplantationMSC + pioglitazone therapycell injection-Royan Institute-liver cirrhosis
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on autologous bone marrow mesenchymal stem cells + pioglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow mesenchymal stem cells + pioglitazone.